VTGN — Vistagen Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $85.70m
- $5.22m
- $0.49m
Annual income statement for Vistagen Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.09 | 1.11 | -0.227 | 1.06 | 0.486 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 19 | 48.9 | 59 | 34.1 | 56.5 |
| Operating Profit | -17.9 | -47.8 | -59.3 | -33 | -56 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.9 | -47.8 | -59.2 | -29.4 | -51.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.9 | -47.8 | -59.2 | -29.4 | -51.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.9 | -47.8 | -59.2 | -29.4 | -51.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.3 | -48.7 | -59.2 | -29.4 | -51.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14.7 | -7.38 | -8.51 | -1.52 | -1.67 |